Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: How much ciprofloxacin is enough?

Intensive Care Medicine

Volumn 28, Issue 4, 2002, Pages 493-500

  Lipman, J ^a   Gous, A ^b   Mathivha, L ^c   Tshukutsoane, S ^c   Scribante, J ^c   Hon, H ^c   Pinder, M ^c   Riera Fanego, J ^c   Verhoef, L ^d   Stass, H ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d South Africa   (South Africa)

Author keywords

Antibiotics; Ciprofloxacin; Paediatrics; Pharmacokinetics; Quinolones; Sepsis

Indexed keywords

CIPROFLOXACIN;

AREA UNDER THE CURVE; ARTHROPATHY; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MALE; PEDIATRICS; PRESCHOOL CHILD; SEIZURE; SEPSIS;

ANTI-INFECTIVE AGENTS; CHILD, PRESCHOOL; CIPROFLOXACIN; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; SEIZURES; SEPSIS;

EID: 0036217523     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1212-y     Document Type: Article

References (35)

1. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability
2. The rise in bacterial resistance is partly because there have been no new classes of antibiotics since the 1960s
3. Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use - Safety report
4. Ciprofloxacin safety in a pediatric population
5. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
6. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation
7. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients
8. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children
9. The selection of appropriate dosages for intravenous ciprofloxacin
10. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
11. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime
12. Dosing considerations with intravenous ciprofloxacin in critical care patients
13. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300- and 400-mg intravenous doses
14. Should quinolones be used in the treatment of bacterial infections in neutropenic patients?
15. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters
16. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
17. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis
18. Role of the new quinolones in pediatric practice
19. Pathophysiology of body fluids and fluid therapy
20. Subtleties of antibiotic dosages - Do doses and intervals make a difference in the critically ill?
21. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
22. Impact of dosage schedule of antibiotics on the treatment of serious infections
23. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa
24. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats
25. Questioning dosing regimens of ciprofloxacin
26. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria
27. Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously
28. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin
29. Pharmacokinetics and pharmacodynamics of fluoroquinolones
30. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens
31. Performance standards for antimicrobial susceptibility testing
32. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa
33. Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinolone-resistant mutations
34. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function
35. The pharmacokinetics of ciprofloxacin in patients with impaired renal function